原始出處紀錄

lebrikizumab · NCT06280716 登錄更新

狀態：ACTIVE_NOT_RECRUITING → COMPLETED；完成日期：2026-08 → 2026-07-16；主要結果：['Percentage of Participants Achieving Eczema Area and Severity Index (EASI-75) (≥75% Reduction in EASI Score) for Mono Cohort', 'Percentage of Participants Achieving EASI-75 for Combo Cohort', 'Percentage of Participants Achieving IGA Score of 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 for Mono Cohort', 'Percentage of Participants Achieving IGA Score of 0 or 1 and a Reduction of ≥2 Points From Baseline to Week 16 for Combo Cohort'] → ['在第 16 週達到濕疹面積與嚴重度指數 (EASI)-75（從基線 EASI 分數降低 ≥75%）的參與者百分比（合併隊列：安慰劑 + TCS 對比 250 mg Lebrikizumab + TCS；單一療法隊列：安慰劑對比 250 mg Lebrikizumab）']